Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16698000 | 0.81 | PTGS2 (0.44) | ALDH1A1TDP1MAPK1TP53TSHR | |
| SCHEMBL796429 | 0.80 | ALDH1A1 (0.64) | ALDH1A1TDP1CYP3A4MAPK1L3MBTL1 | |
| SCHEMBL4882444 | 0.77 | ALDH1A1 (0.45) | ALDH1A1TDP1CYP3A4MAPK1TP53 | |
| SCHEMBL795537 | 0.77 | ALDH1A1 (0.50) | ALDH1A1TDP1CYP3A4MAPK1L3MBTL1 | |
| SCHEMBL8973771 | 0.76 | ALDH1A1 (0.59) | ALDH1A1TDP1CYP3A4MAPK1L3MBTL1 | |
| SCHEMBL8119143 | 0.74 | ALDH1A1 (0.50) | ALDH1A1TDP1CYP3A4MAPK1TP53 | |
| SCHEMBL7877908 | 0.73 | ALDH1A1 (0.68) | ALDH1A1TDP1CYP3A4MAPK1TP53 | |
| SCHEMBL64766 | 0.73 | ALDH1A1 (0.68) | ALDH1A1TDP1CYP3A4MAPK1TP53 | |
| SCHEMBL21474106 | 0.73 | ALDH1A1 (0.68) | ALDH1A1TDP1CYP3A4MAPK1TP53 | |
| SCHEMBL14869755 | 0.73 | NPC1 (0.47) | ALDH1A1CYP3A4MAPK1L3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260126453-A1 | Mass Spectrometry Kit Including a Cross-linked Antibody or Fragment Thereof | THE BINDING SITE GROUP LTD (GB) | 2026-05-07 | — | — | US | disclosed |
| EP-4675278-A2 | ASSAY FOR PLASMA CELL ASSOCIATED DISEASE | The Binding Site Group Limited (GB) | 2026-01-07 | — | — | EP | disclosed |
| US-12461108-B2 | Mass spectrometry kit including a cross-linked antibody or fragment thereof | THE BINDING SITE GROUP LIMITED (GB) | 2025-11-04 | — | — | US | disclosed |
| US-20230391851-A1 | ANTIBODIES | THE BINDING SITE GROUP LIMITED (GB) | 2023-12-07 | — | — | US | disclosed |
| CN-116148479-A | Mass spectrometry kit | 拜恩顶赛集团有限公司 | 2023-05-23 | — | — | CN | disclosed |
| EP-3420362-B1 | ANTIBODIES | THE BINDING SITE GROUP LTD (GB) | 2023-03-22 | — | — | EP | disclosed |
| US-20230080943-A1 | ASSAY FOR PLASMA CELL ASSOCIATED DISEASE | THE BINDING SITE GROUP LIMITED (GB) | 2023-03-16 | — | — | US | disclosed |
| EP-4123308-A1 | MASS SPECTROMETRY KIT | The Binding Site Group Limited (GB) | 2023-01-25 | — | — | EP | disclosed |
| EP-3420361-B1 | MASS SPECTROMETRY KIT | THE BINDING SITE GROUP LTD (GB) | 2023-01-04 | — | — | EP | disclosed |
| EP-4071478-A1 | ASSAY FOR PLASMA CELL ASSSOCIATED DISEASE | The Binding Site Group Limited (GB) | 2022-10-12 | — | — | EP | disclosed |
| EP-3631452-B1 | ASSAY FOR PLASMA CELL ASSOCIATED DISEASE | THE BINDING SITE GROUP LTD (GB) | 2022-07-13 | — | — | EP | disclosed |
| EP-3631452-A1 | ASSAY FOR PLASMA CELL ASSOCIATED DISEASE | The Binding Site Group Limited (GB) | 2020-04-08 | — | — | EP | disclosed |
| CN-110945360-A | Determination of plasma cell related diseases | 结合点集团有限公司 | 2020-03-31 | — | — | CN | disclosed |
| US-20200096520-A1 | ASSAY FOR PLASMA CELL ASSOCIATED DISEASE | BINDING SITE GROUP LIMITED, THE (GB) | 2020-03-26 | — | — | US | disclosed |
| US-20190094239-A1 | MASS SPECTROMETRY KIT | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2019-03-28 | — | — | US | disclosed |
| US-20190048064-A1 | ANTIBODIES | THE BINDING SITE GROUP LIMITED (GB) | 2019-02-14 | — | — | US | disclosed |
| WO-2018215768-A1 | ASSAY FOR PLASMA CELL ASSOCIATED DISEASE | THE BINDING SITE GROUP LIMITED (GB) | 2018-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260126453-A1 | Mass Spectrometry Kit Including a Cross-linked Antibody or Fragment Thereof | IGLV6-57, IGSF11, FCGR3B | ALDH1A1 2401/4885TDP1 3981/4885CYP3A4 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.